Stem cell paracrine activity is implicated in cardiac repair. Linkage between secretome functionality and therapeutic outcome was here interrogated by systems analytics of biobanked human cardiopoietic cells, a regenerative biologic in advanced clinical trials. Protein chip array identified 155 proteins differentially secreted by cardiopoietic cells with clinical benefit, expanded into a 520 node network, collectively revealing inherent vasculogenic properties along with cardiac and smooth muscle differentiation and development. Next generation RNA sequencing, refined by pathway analysis, pinpointed miR-146 dependent regulation upstream of the decoded secretome. Intracellular and extracellular integration unmasked commonality across cardio-vasculogenic processes. Mirroring the secretome pattern, infarcted hearts benefiting from cardiopoietic cell therapy restored the disease proteome engaging cardiovascular system functions. The cardiopoietic cell secretome thus confers a therapeutic molecular imprint on recipient hearts, with response informed by predictive systems profiling.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380441 | PMC |
| http://dx.doi.org/10.1002/sctm.20-0509 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decoded cardiopoietic cell secretome linkage to heart repair biosignature.
Stem Cells Transl Med
November 2024
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Cardiopoiesis-primed human stem cells exert sustained benefit in treating heart failure despite limited retention following myocardial delivery. To assess potential paracrine contribution, the secretome of cardiopoiesis conditioned versus naïve human mesenchymal stromal cells was decoded by directed proteomics augmented with machine learning and systems interrogation. Cardiopoiesis doubled cellular protein output generating a distinct secretome that segregated the conditioned state.
View Article and Find Full Text PDFPositron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling.
J Vis Exp
October 2023
Division of Nuclear Medicine, Department of Radiology, Mayo Clinic;
Stem cell and chimeric antigen receptor (CAR) T-cell therapies are emerging as promising therapeutics for organ regeneration and as immunotherapy for various cancers. Despite significant progress having been made in these areas, there is still more to be learned to better understand the pharmacokinetics and pharmacodynamics of the administered therapeutic cells in the living system. For noninvasive, in vivo tracking of cells with positron emission tomography (PET), a novel [Zr]Zr-p-isothiocyanatobenzyl-desferrioxamine ([Zr]Zr-DBN)-mediated cell radiolabeling method has been developed utilizing Zr (t1/2 78.
View Article and Find Full Text PDFOptimized Catheter System Demonstrates Utility for Endomyocardial Delivery of Cardiopoietic Stem Cells in Target Patients With Heart Failure.
Tex Heart Inst J
October 2023
Marriott Heart Disease Research Program, Center for Regenerative Medicine and Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Trans-endocardial delivery of progenitor cells to compromised myocardium using the "needle technique"and risk of myocardial injury.
Postepy Kardiol Interwencyjnej
December 2022
Department of Cardiac and Vascular Diseases, John Paul II Hospital, Krakow, Poland.
Article Synopsis
- The CHART-1 study found that multiple injections of cardiopoetic cells in patients with chronic ischemic heart failure may diminish their therapeutic effects over time.
- Patients with low left ventricular ejection fraction (LVEF) underwent either cell transplantation or a sham procedure, and their heart function was assessed using echocardiography.
- Results indicated that a significant percentage of those receiving cardiopoetic cells experienced decreased heart contractility and increased wall motion score, suggesting that the injection technique may cause myocardial injury that outweighs potential benefits.
Mass Customized Outlook for Regenerative Heart Failure Care.
Int J Mol Sci
October 2021
Center for Regenerative Medicine, Marriott Family Comprehensive Cardiac Regenerative Medicine, Marriott Heart Disease Research Program, Van Cleve Cardiac Regenerative Medicine Program, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Heart failure pathobiology is permissive to reparative intent. Regenerative therapies exemplify an emerging disruptive innovation aimed at achieving structural and functional organ restitution. However, mixed outcomes, complexity in use, and unsustainable cost have curtailed broader adoption, mandating the development of novel cardio-regenerative approaches.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!